John D. Graham - Concepedia

Author

John D. Graham

Also Known As

B R Graham, Graham, J. D., Graham, JMR, Graham, John, Graham, John D., J D GRAHAM, J D Graham, J D P GRAHAM, J D P Graham, J Graham

398

Publications

15.4K

Citations

H-Index

312

Concepts

All Affiliations

Cardiff University Institute of Cancer Research Beatson West of Scotland Cancer Centre Royal Marsden NHS Foundation Trust Harvard University

About

John D. Graham is an author at Cardiff University specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	13	14	2.2K
2	Engineering	10	10	405
3	Business	7	7	117
4	Arts	1	1	100
5	Education	1	1	10

John D. Graham

150

Publications

13.4K

Citations

H-Index

Page 1

	Year	Citations
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, The Lancet	2015	1.9K
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial David P. Dearnaley, Isabel Syndikus, Helen Mossop, The Lancet Oncology	2016	1.3K
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial David P. Dearnaley, Matthew R. Sydes, John D. Graham, The Lancet Oncology Radiation TherapyMedicineMrc Rt01Radiation Therapy PlanningComparative Planning	2007	904
Psychometric scores and persistence of irritable bowel after infectious diarrhoea Kok‐Ann Gwee, John D. Graham, M W McKendrick, The Lancet Psychometric ScoresFunctional Gastrointestinal DisorderGastroenterologyUlcerative ColitisMedicine	1996	463
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial David P. Dearnaley, Gordana Jovic, Isabel Syndikus, The Lancet Oncology	2014	453
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial R.T.D. Oliver, MD Mason, GM Mead, The Lancet Surgical OncologyRadiation TherapyMedicineRandomised TrialAdjuvant Treatment	2005	445
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst, The Lancet Oncology Radical CystectomyUrologySurgical OncologyGenitourinary CancerMedicine	2014	381
Willingness to Pay for Health Protection: Inadequate Sensitivity to Probability? James K. Hammitt, John D. Graham Journal of Risk and Uncertainty	1999	343
Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancer Sara Ramsey, Gavin W.A. Lamb, Michael Aitchison, Cancer	2006	328
Valuing Mortality-Risk Reduction: Using Visual Aids to Improve the Validity of Contingent Valuation Phaedra S. Corso, James K. Hammitt, John D. Graham Journal of Risk and Uncertainty	2001	293

Page 1